Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Symphogen Receives $5M Milestone from Genentech | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Symphogen Receives $5M Milestone from Genentech

The payment is related to a potential treatment of Staphylococcus aureus infections

By: Betsy Louda

, Contract Pharma

Symphogen has received a $5 million milestone payment from Genentech, triggered by the initiation of a Phase 1b clinical trial evaluating DSTA4637S, an investigational medicine containing a Symphogen-generated antibody conjugated to an antibiotic agent for the potential treatment of Staphylococcus aureus infections.

 

The antibody was originally discovered by isolating antibodies from individuals exposed to S.aureus using Symphogen’s patented Symplex technology.

 

“Genentech’s decision to move this exciting new investigational medicine forward is an important advancement for Symphogen’s technology platform which underpins our antibody discovery and development work.” said Martin Olin, chief executive officer of Symphogem. “This represents an important step forward in addressing the unmet need associated with serious S. aureus infections, potentially improving outcomes for patients with the disease.”

 

Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use in oncology.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics